Critical role of preproenkephalin in experimental autoimmune  encephalomyelitis

Author(s): Weir C1, McNeill A, Hook S, Harvie M, La Flamme AC, et al. 

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an organ-specific autoimmune disease model used to investigate mechanisms involved in the activation of self-reactive T cells. Preproenkephalin (PPNK) is the gene that encodes the protein proenkephalin A that has been detected in the brain, adrenal cells and cells of the immune system. In this paper, whether PPNK plays a role in the development of EAE was investigated. PPNK-deficient and wild-type mice were immunized with the MOG(35-55) peptide and the development of EAE observed. Our results show that PPNK-deficient mice developed less severe clinical signs of disease than wild-type mice, and with lower incidence. MOG(35-55)-specific T cells from PPNK-deficient and wild-type mice produced IFNgamma and TNFalpha but no IL-4 or IL-10, indicative of a Th1 phenotype. However, the numbers of MOG(35-55)-specific IFNgamma-producing cells from immunized PPNK-deficient mice were largely reduced at early stages of disease. Interestingly, there was no difference in clinical signs or infiltrating mononuclear cells in the CNS between wild-type and PPNK-deficient mice at the later stage of disease. Our results suggest that PPNK accelerates the generation of autoimmune IFNgamma-producing T cells and MOG(35-55)-induced EAE.

Similar Articles

SOD1 and amyotrophic lateral sclerosis: mutations and  oligomerization

Author(s): Banci L, Bertini I, Boca M, Girotto S, Martinelli M, et  al.

Oral treatment  for multiple sclerosis

Author(s): Killestein J, Rudick RA, Polman CH

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple  sclerosis (MS)

Author(s): Constantinescu CS, Farooqi N, O'Brien K, Gran B

Variable effects of cyclophosphamide in rodent models of  experimental allergic encephalomyelitis

Author(s): Mangano K, Nicoletti A, Patti F, Donia M, Malaguarnera L,  et al.

[Study of cellular immunity and the opioid peptide system in patients  with multiple sclerosis]

Author(s): Demina TL, BoÄ­ko AN, Rossel's AN, Balashov KE, Popova NF 

The immunoregulatory abilities of polymorphonuclear neutrophils in  the course of multiple sclerosis

Author(s): Ziaber J, PaÅ›nik J, Baj Z, Pokoca L, Chmielewski H, et  al.

Structural analysis of neprilysin with various specific and potent inhibitors

Author(s): Oefner C, Roques BP, Fournie-Zaluski MC, Dale GE

The biology  of the opioid growth factor receptor (OGFr)

Author(s): Zagon IS, Verderame MF, McLaughlin PJ

Opioid growth factor suppresses expression of experimental autoimmune  encephalomyelitis

Author(s): Zagon IS, Rahn KA, Bonneau RH, Turel AP, McLaughlin PJ